CHDI-00484077, with the CAS number 3025894-92-9, is a chemical compound that has been studied primarily in the context of neurodegenerative diseases, particularly Huntington's disease. It is classified as a small molecule inhibitor, specifically targeting certain biological pathways involved in the disease's progression. The compound is designed to modulate protein interactions and cellular processes that contribute to neurodegeneration. Its mechanism of action typically involves the inhibition of specific enzymes or receptors, which can lead to neuroprotective effects. In preclinical studies, CHDI-00484077 has shown promise in improving cellular health and function in models of Huntington's disease. The compound's solubility, stability, and bioavailability are important characteristics that influence its potential therapeutic applications. Ongoing research aims to further elucidate its pharmacokinetics, efficacy, and safety profile, which are crucial for its development as a treatment option. Overall, CHDI-00484077 represents a significant focus in the search for effective therapies for neurodegenerative disorders.

CHDI 00484077

3025894-92-9: CHDI-00484077, with the CAS number 3025894-92-9, is a chemical compound that has been studied primarily in the context of neurodegenerative diseases, particularly Huntington's disease. It is classified as a small molecule inhibitor, specifically targeting certain biological pathways involved in the disease's progression. The compound is designed to modulate protein interactions and cellular processes that contribute to neurodegeneration. Its mechanism of action typically involves the inhibition of specific enzymes or receptors, which can lead to neuroprotective effects. In preclinical studies, CHDI-00484077 has shown promise in improving cellular health and function in models of Huntington's disease. The compound's solubility, stability, and bioavailability are important characteristics that influence its potential therapeutic applications. Ongoing research aims to further elucidate its pharmacokinetics, efficacy, and safety profile, which are crucial for its development as a treatment option. Overall, CHDI-00484077 represents a significant focus in the search for effective therapies for neurodegenerative disorders.

<p>CHDI 00484077 is a highly selective, central nervous system (CNS) permeable Class IIa HDAC inhibitor, and can be used to study Huntington's disease.</p>

CAS 3025894-92-9

CHDI 00484077

CHDI 00484077

Ref: TM-T83946

CHDI 00484077

Ref: 54-BUP20294